Cart
0

Scleroderma Diagnostics and Therapeutics Market by Disease Type (Localized Scleroderma and Systemic Scleroderma), by Drugs (Corticosteroids, Immunosuppressive Agents, Endothelin Receptor Antagonists, Calcium Channel Blockers, PDE-5 Inhibitors, Chelating Agents, Prostacyclin Analogues, and Others) and by Diagnosis (Antibodies Tests/Blood Tests, Capillaroscopy, Cardiac Diagnosis, Gastrointestinal Diagnosis, Imaging, Pulmonary Diagnosis, Skin Viscoelasticity, and General) - Global Opportunity Analysis and Industry Forecast, 2017-2023

Get 20% Free Customization In This Report
LI_184213
Pages: NA
Jan 2019 | 461 Views
 
Author's : NA
Tables: NA
Charts: NA
 

Scleroderma is an autoimmune rheumatic disorder that causes chronic hardening and tightening of the skin and connective tissues. The precise cause of Scleroderma is unknown however, it involves overproduction of collagen. It may cause damage to the internal organs such as blood vessels, heart, lungs, stomach, and kidney. The occurrences of scleroderma in women is four times more compared to men. Furthermore, the onset is more frequent between age group of 30 and 50.

Increase in incidences of Scleroderma majorly drives the market growth. Scleroderma is a long-term disease and requires daily dose of drugs. Furthermore, rise in awareness of preventive healthcare and increase in disposable income among the population is anticipated to increase the scleroderma diagnostics and therapeutics market. Furthermore, the stringent government regulations, adverse effects of drugs, high healthcare cost, and diagnostic test of Scleroderma are major barriers for the growth of the market. Ongoing, R&D in the field of Scleroderma diagnosis and therapeutics is anticipated to create new opportunities during the forecast period.

The market is segmented on the basis of disease type, drugs, diagnosis, and geography. Based on disease type, the market is divided into localized scleroderma and systemic scleroderma. Based on drugs, the market is segmented into corticosteroids, immunosuppressive agents, endothelin receptor antagonists, calcium channel blockers, PDE-5 inhibitors, chelating agents, prostacyclin analogues, and others.

Based on diagnosis, the market is categorized into antibodies test/blood tests, capillaroscopy, cardiac diagnosis, gastrointestinal diagnosis, imaging (CT, MRI), pulmonary diagnosis, skin viscoelasticity, and general. By geography, it is analysed across North America, Europe, Asia-Pacific, and LAMEA.

Key Benefits

  • The study provides an in-depth analysis of the global scleroderma diagnostics and therapeutics market, with current trends and future estimations to elucidate the investment pockets.
  • Comprehensive analysis of factors that drive and restrict the growth of the market is provided.
  • The report provides a quantitative analysis to help the stakeholders capitalize on prevailing market opportunities.
  • Extensive analysis of different segments facilitates to understand various products of the market.
  • Key players are profiled and their strategies are analyzed thoroughly, which predict the competitive outlook of the market.

Scleroderma Diagnostics And Therapeutics Market Key Segment:

By Disease Type

  • Localized Scleroderma
    • Morphea
    • Linear Scleroderma
  • Systemic Scleroderma
    • Diffused Scleroderma
    • Limited Scleroderma

By Drugs

  • Corticosteroids
  • Immunosuppressive Agents
  • Endothelin Receptor Antagonists
  • Calcium Channel Blockers
  • PDE-5 Inhibitors
  • Chelating Agents
  • Prostacyclin Analogues
  • Others (H2 Blockers, Proton Pump Inhibitors, Ace Inhibitors, and Others)

By Diagnosis

  • Antibodies Tests/Blood Tests
  • Capillaroscopy
  • Cardiac Diagnosis
  • Gastrointestinal Diagnosis
  • Imaging (CT and MRI)
  • Pulmonary Diagnosis
  • Skin Viscoelasticity
  • General
    • Electromyography
    • Dubious Diagnostic Tests

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Rest of Asia-Pacific
  • LAMEA
    • Latin America
    • Middle East
    • Africa

List of players profiled in the report

  • Actelion Pharmaceuticals, Inc.
  • Boehringer Ingelheim
  • Bayer AG
  • Cytori Therapeutics, Inc.
  • Cumberland Pharmaceuticals Inc.
  • Gilead Sciences, Inc.
  • Pfizer, Inc.
  • Active Biotech AB
  • BioLineRx, Ltd.
  • Bristol-Myers Squibb Company
 

Chapter: 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

Chapter: 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

Chapter: 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. MARKET SHARE ANALYSIS, 2016
3.4.  PORTER’S FIVE FORCES ANALYSIS
3.5. MARKET DYNAMICS

3.5.1. Drivers
3.5.2. Restraints
3.5.3. Opportunities

Chapter: 4 SCLERODERMA DIAGNOSTICS AND THERAPEUTICS MARKET, BY DISEASE TYPE

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. LOCALISED SCLERODERMA

4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast
4.2.4. Morphea

4.2.4.1. Market size and forecast

4.2.5. Linear Scleroderma

4.2.5.1. Market size and forecast

4.3. SYSTEMIC SCLERODERMA

4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast
4.3.4. Diffused Scleroderma

4.3.4.1. Market size and forecast

4.3.5. Limited Scleroderma

4.3.5.1. Market size and forecast

Chapter: 5 SCLERODERMA DIAGNOSTICS AND THERAPEUTICS MARKET, BY DRUGS

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2. CORTICOSTEROIDS

5.2.1. Market size and forecast

5.3. IMMUNOSUPPRESSIVE AGENTS

5.3.1. Market size and forecast

5.4. ENDOTHELIN RECEPTOR ANTAGONISTS

5.4.1. Market size and forecast

5.5. CALCIUM CHANNEL BLOCKERS

5.5.1. Market size and forecast

5.6. PDE-5 INHIBITORS

5.6.1. Market size and forecast

5.7. CHELATING AGENTS

5.7.1. Market size and forecast

5.8. PROSTACYCLIN ANALOGUES

5.8.1. Market size and forecast

5.9. OTHERS

5.9.1. Market size and forecast

Chapter: 6 SCLERODERMA DIAGNOSTICS AND THERAPEUTICS MARKET, BY DIAGNOSIS

6.1. OVERVIEW

6.1.1. Market size and forecast

6.2. ANTIBODIES TESTS/BLOOD TESTS

6.2.1. Market size and forecast

6.3. CAPILLAROSCOPY

6.3.1. Market size and forecast

6.4. CARDIAC DIAGNOSIS

6.4.1. Market size and forecast

6.5. GASTROINTESTINAL DIAGNOSIS

6.5.1. Market size and forecast

6.6. IMAGING (CT, AND MRI)

6.6.1. Market size and forecast

6.7. PULMONARY DIAGNOSIS

6.7.1. Market size and forecast

6.8. SKIN VISCOELASTICITY

6.8.1. Market size and forecast

6.9. GENERAL

6.9.1. Market size and forecast
6.9.2. Electromyography

6.9.2.1. Market size and forecast

6.9.3. Dubious Diagnostic Tests

6.9.3.1. Market size and forecast

Chapter: 7 SCLERODERMA DIAGNOSTICS AND THERAPEUTICS MARKET, BY GEOGRAPHY

7.1. OVERVIEW
7.2. NORTH AMERICA

7.2.1. Key market trends
7.2.2. Key growth factors and opportunities
7.2.3. Market size and forecast

7.2.3.1. U.S. market size and forecast
7.2.3.2. Canada market size and forecast
7.2.3.3. Mexico market size and forecast

7.2.4. North America Scleroderma Diagnostics and Therapeutics Market by Disease Type
7.2.5. North America Scleroderma Diagnostics and Therapeutics Market by Drugs
7.2.6. North America Scleroderma Diagnostics and Therapeutics Market by Diagnosis

7.3. EUROPE

7.3.1. Key market trends
7.3.2. Key growth factors and opportunities
7.3.3. Market size and forecast

7.3.3.1. Germany market size and forecast
7.3.3.2. France market size and forecast
7.3.3.3. UK market size and forecast
7.3.3.4. Italy market size and forecast
7.3.3.5. Spain market size and forecast
7.3.3.6. Rest of Europe market size and forecast

7.3.4. Europe Scleroderma Diagnostics and Therapeutics Market by Disease Type
7.3.5. Europe Scleroderma Diagnostics and Therapeutics Market by Drugs
7.3.6. Europe Scleroderma Diagnostics and Therapeutics Market by Diagnosis

7.4. ASIA-PACIFIC

7.4.1. Key market trends
7.4.2. Key growth factors and opportunities
7.4.3. Market size and forecast

7.4.3.1. Japan market size and forecast
7.4.3.2. China market size and forecast
7.4.3.3. India market size and forecast
7.4.3.4. Rest of Asia-Pacific market size and forecast

7.4.4. Asia-Pacific Scleroderma Diagnostics and Therapeutics Market by Disease Type
7.4.5. Asia-Pacific Scleroderma Diagnostics and Therapeutics Market by Drugs
7.4.6. Asia-Pacific Scleroderma Diagnostics and Therapeutics Market by Diagnosis

7.5. LAMEA

7.5.1. Key market trends
7.5.2. Key growth factors and opportunities
7.5.3. Market size and forecast

7.5.3.1. Latin America market size and forecast
7.5.3.2. Middle East market size and forecast
7.5.3.3. Africa market size and forecast

7.5.4. LAMEA Scleroderma Diagnostics and Therapeutics Market by Disease Type
7.5.5. LAMEA Scleroderma Diagnostics and Therapeutics Market by Drugs
7.5.6. LAMEA Scleroderma Diagnostics and Therapeutics Market by Diagnosis

Chapter: 8 COMPANY PROFILES

8.1. ACTELION PHARMACEUTICALS, INC.

8.1.1. Operating business segments
8.1.2. Business performance
8.1.3. Key strategic moves and developments

8.2. BOEHRINGER INGELHEIM

8.2.1. Operating business segments
8.2.2. Business performance
8.2.3. Key strategic moves and developments

8.3. BAYER AG

8.3.1. Operating business segments
8.3.2. Business performance
8.3.3. Key strategic moves and developments

8.4. CYTORI THERAPEUTICS, INC.

8.4.1. Operating business segments
8.4.2. Business performance
8.4.3. Key strategic moves and developments

8.5. CUMBERLAND PHARMACEUTICALS INC.

8.5.1. Operating business segments
8.5.2. Business performance
8.5.3. Key strategic moves and developments

8.6. GILEAD SCIENCES, INC.

8.6.1. Operating business segments
8.6.2. Business performance
8.6.3. Key strategic moves and developments

8.7. PFIZER, INC.

8.7.1. Operating business segments
8.7.2. Business performance
8.7.3. Key strategic moves and developments

8.8. ACTIVE BIOTECH AB

8.8.1. Operating business segments
8.8.2. Business performance
8.8.3. Key strategic moves and developments

8.9. BIOLINERX, LTD.

8.9.1. Operating business segments
8.9.2. Business performance
8.9.3. Key strategic moves and developments

8.10. BRISTOL-MYERS SQUIBB COMPANY

8.10.1. Operating business segments
8.10.2. Business performance
8.10.3. Key strategic moves and developments

 
With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace


With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast


Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts


Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)


Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.
 

PURCHASE OPTIONS

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,    Int'l : +1-503-894-6022
Drop us an email at
help@alliedmarketresearch.com

Send Enquiry
 

Request TOC/Sample

Request Customization

Request TOC/Sample

OR

Purchase Full Report of
Scleroderma Diagnostics and Therapeutics Market- Global Opportunity Analysis and Industry Forecast, 2017-2023

  • Online Only
  • $3456 $3111
  • Online cloud Access only
  • Restricted Print, copy, paste,download
  • Read Only
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Data Pack
  • $3840 $3456
  • Restricted to one authorized users
  • One print only
  • Available in Excel
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Single User
  • $5370 $4833
  • Restricted to one authorized users
  • One print only
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Five User
  • $6450 $5805
  • Limited to 5 authorized users
  • Print Upto Five Copies
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Enterprise
    License/PDF

  • $8995 $8096
  • Unlimited within company/enterprise
  • Unlimited within company/enterprise
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 
 

FREQUENTLY ASKED
QUESTIONS?

 
 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 
 
 

Why Allied Market Research

 

Infallible Methodology

To ensure high level data integrity, accurate analysis and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 
 

Featured Readings

 

Get Fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts
 

Access reports on all emerging
market of Life Sciences on Knowledge Tree Platform
Free Demo